Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response

Oncotarget

Volumn 6, Issue 7, 2015, Pages 5059-5071

  Mensah, Afua Adjeiwaa ^a   Kwee, Ivo ^a,b   Gaudio, Eugenio ^a   Rinaldi, Andrea ^a   Ponzoni, Maurilio ^c   Cascione, Luciano ^a,d   Fossati, Gianluca ^e   Stathis, Anastasios ^d   Zucca, Emanuele ^d   Caprini, Gianluca ^e   Bertoni, Francesco ^a,d  

^a INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^b DALLE MOLLE INSTITUTE FOR ARTIFICIAL INTELLIGENCE IDSIA   (Switzerland)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^e Italfarmaco SpA   (Italy)

Author keywords

CDKN1A; Histone deacetylase; MYC; NFKB; STAT3

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE DEACETYLASE INHIBITOR; ITF A; ITF B; METALLOTHIONEIN; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER MODEL; CDKN1A GENE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CHROMATIN STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOMA CELL LINE; PHARMACOGENETICS; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION PROFILING; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; TREATMENT OUTCOME;

EID: 84924973685     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le Gouill S, Iannitto E, Pileri S, Rodriguez J, Schmitz N, Wotherspoon A, Zinzani P and Zucca E. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013; 24(4):857-877.
2. Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013; 24(3):561-576.
3. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011; 476(7360):298-303.
4. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011; 471(7337):189-195.
5. Barneda-Zahonero B and Parra M. Histone deacetylases and cancer. Mol Oncol. 2012; 6(6):579-589.
6. Dell'Aversana C, Lepore I and Altucci L. HDAC modulation and cell death in the clinic. Exp Cell Res. 2012; 318(11):1229-1244.
7. Gloghini A, Buglio D, Khaskhely NM, Georgakis G, Orlowski RZ, Neelapu SS, Carbone A and Younes A. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. British journal of haematology. 2009; 147(4):515-525.
8. Marquard L, Poulsen CB, Gjerdrum LM, de Nully Brown P, Christensen IJ, Jensen PB, Sehested M, Johansen P and Ralfkiaer E. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology. 2009; 54(6):688-698.
9. Lee SH, Yoo C, Im S, Jung JH, Choi HJ and Yoo J. Expression of Histone Deacetylases in Diffuse Large B-cell Lymphoma and Its Clinical Significance. International journal of medical sciences. 2014; 11(10):994-1000.
10. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA and Marks PA. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(12):5705-5708.
11. Dickinson M, Johnstone RW and Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs. 2010; 28 Suppl 1:S3-20.
12. Falkenberg KJ and Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nature reviews Drug discovery. 2014; 13(9):673-691.
13. Vesci L, Bernasconi E, Milazzo FM, De Santis R, Gaudio E, Kwee I, Rinaldi A, Pace S, Carollo V, Giannini G and Bertoni F. Preclinical antitumor activity of ST7612AA1: a novel second generation oral histone deacetylase (HDAC) inhibitor. Oncotarget. 2014.
14. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM and Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(21):3109-3115.
15. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009; 27(32):5410-5417.
16. McDermott J and Jimeno A. Belinostat for the treatment of peripheral T-cell lymphomas. Drugs of today. 2014; 50(5):337-345.
17. Kalac M, Scotto L, Marchi E, Amengual J, Seshan VE, Bhagat G, Ulahannan N, Leshchenko VV, Temkin AM, Parekh S, Tycko B and O'Connor OA. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood. 2011; 118(20):5506-5516.
18. Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res. 2009; 15(12):3947-3957.
19. Burgess AJ, Pavey S, Warrener R, Hunter LJ, Piva TJ, Musgrove EA, Saunders N, Parsons PG and Gabrielli BG. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Molecular pharmacology. 2001; 60(4):828-837.
20. Tula-Sanchez AA, Havas AP, Alonge PJ, Klein ME, Doctor SR, Pinkston W, Glinsmann-Gibson BJ, Rimsza LM and Smith CL. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors. Cancer Biol Ther. 2013; 14(10):949-961.
21. Duan H, Heckman CA and Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Molecular and cellular biology. 2005; 25(5):1608-1619.
22. Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P and Garcia-Manero G. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound beta-phenylethyl isothiocyanate. Blood. 2010; 116(15):2732-2741.
23. Thompson RC, Vardinogiannis I and Gilmore TD. The Sensitivity of Diffuse Large B-Cell Lymphoma Cell Lines to Histone Deacetylase Inhibitor-Induced Apoptosis Is Modulated by BCL-2 Family Protein Activity. PLoS One. 2013; 8(5):e62822.
24. Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S and Anderson KC. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013; 37(7):829-837.
25. Heller G, Schmidt WM, Ziegler B, Holzer S, Mullauer L, Bilban M, Zielinski CC, Drach J and Zochbauer-Muller S. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res. 2008; 68(1):44-54.
26. Lee JH, Choy ML and Marks PA. Mechanisms of resistance to histone deacetylase inhibitors. Advances in cancer research. 2012; 116:39-86.
27. Ghoshal K, Datta J, Majumder S, Bai S, Dong X, Parthun M and Jacob ST. Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Molecular and cellular biology. 2002; 22(23):8302-8319.
28. Takahashi S. Molecular functions of metallothionein and its role in hematological malignancies. Journal of hematology & oncology. 2012; 5:41.
29. Stapnes C, Ryningen A, Hatfield K, Oyan AM, Eide GE, Corbascio M, Kalland KH, Gjertsen BT and Bruserud O. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. International journal of oncology. 2007; 31(6):1529-1538.
30. Boyd MR and Paull KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Development Research. 1995; 34(2):91-109.
31. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA and Schrump DS. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst. 2002; 94(7):504-513.
32. Nguyen DM, Schrump WD, Chen GA, Tsai W, Nguyen P, Trepel JB and Schrump DS. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10(5):1813-1825.
33. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL, Pellegrini M, Wei A, Richon VM, Marks PA, Lowe SW, Smyth MJ, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(19):8071-8076.
34. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008; 111(3):1060-1066.
35. Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbo F, Piva R, Rancoita PM, Matolcsy A, Timar B, Tousseyn T, Rodriguez-Pinilla SM, Piris MA, Bea S, Campo E, Bhagat G, et al. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood. 2013; 122(15):2683-2693.
36. Gentleman R CV, Dudoit S, Irizarry R, Huber W eds. (2005). Bioinformatics and Computational Biology Solutions using R and Bioconductor. Statistics for Biology and Health. (New York, NY, USA: Springer).
37. Johnson WE, Li C and Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007; 8(1):118-127.
38. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical applications in genetics and molecular biology. 2004; 3:Article3.
39. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34(3):267-273.
40. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-15550.